ReviewFrontiers in pharmacology2026
Inhibiting the pathological changes of PASMCs is an effective approach for medicinal plants or secondary metabolites in treating pulmonary hypertension.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary hypertension (PH) is a progressive cardiovascular disease characterized by increased pulmonary vascular resistance and structural remodeling of pulmonary vessels, leading to poor clinical outcomes and high mortality. pulmonary artery smooth muscle cells (PASMCs) migration, apoptosis and abnormal proliferation are the main pathological features leading to the occurrence of PH. Increasing evidence suggests that inhibition of PASMCs pathological changes contributes to the improvement of PH. However, the current clinical treatment of PH is limited, and medicinal plants or secondary metabolites are gradually recognized as potential treatment options for PH. Therefore, this article focuses on inhibiting the abnormal pathological changes of PASMCs, and analyzes and summarizes the mechanism and process of medicinal plants or secondary metabolites in the treatment of PH by inhibiting the abnormal proliferation of PASMCs, so as to provide a direction for the development of medicinal plants or secondary metabolites for the treatment of PH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.